<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1405-0099</journal-id>
<journal-title><![CDATA[Cirujano general]]></journal-title>
<abbrev-journal-title><![CDATA[Cir. gen]]></abbrev-journal-title>
<issn>1405-0099</issn>
<publisher>
<publisher-name><![CDATA[Asociación Mexicana de Cirugía General A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1405-00992014000300138</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Citorreducción e HIPEC en carcinomatosis peritoneal. Experiencia del Instituto Nacional de Cancerología de México]]></article-title>
<article-title xml:lang="en"><![CDATA[Cytoreduction and HIPEC in peritoneal carcinomatosis. Experience in the National Cancer Institute of Mexico]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[López-Basave]]></surname>
<given-names><![CDATA[Horacio Noé]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Morales-Vásquez]]></surname>
<given-names><![CDATA[Flavia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Luna Ortiz]]></surname>
<given-names><![CDATA[Kuauhyama]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Méndez Herrera]]></surname>
<given-names><![CDATA[Carmen]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ruiz-Molina]]></surname>
<given-names><![CDATA[Juan M.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Nacional de Cancerología de México Departamento de Gastroenterología ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto Nacional de Cancerología de México Departamento de Oncología Médica ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Instituto Nacional de Cancerología de México Subdirección de Cirugía ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2014</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2014</year>
</pub-date>
<volume>36</volume>
<numero>3</numero>
<fpage>138</fpage>
<lpage>144</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S1405-00992014000300138&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S1405-00992014000300138&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S1405-00992014000300138&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen Introducción: El diagnóstico del tumor en peritoneo se asocia a mal pronóstico. El manejo establecido es quimioterapia, con resultados limitados. Es necesario ensayar otras opciones: la cirugía citorreductora (CRS) combinada con quimioterapia intraperitoneal con hipertermia (HIPEC) es una opción que mejora la supervivencia. El propósito de este estudio es evaluar la factibilidad y la seguridad de la CRS más HIPEC para la carcinomatosis peritoneal (CP) en el Instituto Nacional de Cancerología de México. Métodos: Se diseñó un estudio piloto para pacientes con CP para tratarlos con HIPEC después de CRS para evaluar seguridad y factibilidad en un centro de referencia. Resultados: Se trató a 39 pacientes de 55.4 (49-67) años de edad promedio. Después de CRS óptima, recibieron HIPEC con cisplatino 25 mg/m2/l y mitomicina C 3.3 mg/m2/l. Hubo complicaciones mayores en el 53% de los casos, sin mortalidad operatoria. El tiempo quirúrgico fue 7.06 (5-9) h. La mediana de sangrado fue 939 (100-3,700) ml. Ameritaron estancia en UCI 2.7 días. La sobrevida media fue de 28 meses, mayor entre los pacientes con índice de carcinomatosis &lt; 20 puntos (32 meses) y menor con un índice &gt; 21 (21 meses). Conclusiones: Se ha demostrado que una adecuada selección de pacientes y un procedimiento uniforme y ordenado de CRS más HIPEC son un procedimiento factible y de benefi cio para los pacientes. El procedimiento es de baja mortalidad y de alta morbilidad, pero mejor que solo terapia sistémica.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Background: The diagnosis of peritoneal carcinomatosis is associated a poor prognosis. The standard treatment is chemotherapy, with limited results. Other options need to be explored, and cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) maybe improve the results. This study evaluated safety and feasibility of CRS with HIPEC for peritoneal metastasis at the National Cancer Institute, Mexico. Methods: In a pilot study of patients with peritoneal carcinomatosis (PC) treated with HIPEC after optimal CRS, a review was performed to evaluate safety and feasibility in a reference center. Results: Thirty-nine patients were treated. The mean age was 55.4 years. After aggressive CRS, HIPEC was performed with cisplatin 25mg/m2/L and mitomycin C 3.3 mg/m2/L Major postoperative complications developed in 53%. No operative mortality occurred. The mean time of the surgical procedure was 7.06 hours (5-9 hours). The median of blood loss was 939 ml (100-3700 ml). The mean ICU stay was 2.7 days. The median survival was 28 months, with 32 months in patients with &lt;20 points on the peritoneal cancer index, and 21 months for patients with index &gt;21. Conclusions: The results underline the safety and effi cacy of CRS and HIPEC for PC. It is feasible and benefi cial for patients in the National Cancer Institute, Mexico. The procedure has a low mortality rate and high morbidity, but is better than systemic therapy only.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Cirugía citorreductora]]></kwd>
<kwd lng="es"><![CDATA[Quimioterapia intraperitoneal con hipertermia]]></kwd>
<kwd lng="es"><![CDATA[Carcinomatosis]]></kwd>
<kwd lng="es"><![CDATA[Morbilidad]]></kwd>
<kwd lng="es"><![CDATA[Mortalidad]]></kwd>
<kwd lng="en"><![CDATA[Cytoreductive surgery]]></kwd>
<kwd lng="en"><![CDATA[Hyperthermic intraperitoneal chemotherapy]]></kwd>
<kwd lng="en"><![CDATA[Carcinomatosis]]></kwd>
<kwd lng="en"><![CDATA[Morbidity]]></kwd>
<kwd lng="en"><![CDATA[Mortality]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sadeghi]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Arvieux]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Glehen]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study]]></article-title>
<source><![CDATA[Cancer]]></source>
<year>2000</year>
<volume>88</volume>
<page-range>358-63</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Jatkie]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Gene expression profi les and molecular markers to predict recurrent of Duke&#8217;s colon cancer]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2004</year>
<page-range>22</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Knorr]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Reingruber]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Meyer]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Peritoneal carcinomatosis of colorectal cancer: incident, prognosis and treatment modalities]]></article-title>
<source><![CDATA[Int J Colorectal Dis]]></source>
<year>2004</year>
<volume>19</volume>
<page-range>181-7</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Glockzin]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Ghali]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Lang]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Peritoneal carcinomatosis. Surgical treatment, including hyperthermic intraperitoneal chemotherapy]]></article-title>
<source><![CDATA[Chirurg]]></source>
<year>2007</year>
<volume>78</volume>
<page-range>1102-6</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bristow]]></surname>
<given-names><![CDATA[RE]]></given-names>
</name>
<name>
<surname><![CDATA[Tomacruz]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Armstrong]]></surname>
<given-names><![CDATA[DK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2002</year>
<volume>20</volume>
<page-range>1248-59</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sugarbaker]]></surname>
<given-names><![CDATA[PH]]></given-names>
</name>
<name>
<surname><![CDATA[Cunliffe]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Belliveau]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rationale for integrating earlypostoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer]]></article-title>
<source><![CDATA[Semin Oncol]]></source>
<year>1989</year>
<volume>16</volume>
<page-range>83-97</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sugarbaker]]></surname>
<given-names><![CDATA[PH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome?]]></article-title>
<source><![CDATA[Lancet Oncol]]></source>
<year>2006</year>
<volume>7</volume>
<page-range>69-76</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Markman]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intraperitoneal chemotherapy]]></article-title>
<source><![CDATA[Semin Oncol]]></source>
<year>1991</year>
<volume>18</volume>
<page-range>248-54</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stephens]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Alderman]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique]]></article-title>
<source><![CDATA[Ann Surg Oncol]]></source>
<year>1999</year>
<volume>6</volume>
<page-range>790-6</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Helm]]></surname>
<given-names><![CDATA[CW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The role of hyperthermic intraperitoneal chemo-therapy (HIPEC) in ovarian cancer]]></article-title>
<source><![CDATA[Oncologist]]></source>
<year>2009</year>
<volume>14</volume>
<page-range>683-94</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gusani]]></surname>
<given-names><![CDATA[NJ]]></given-names>
</name>
<name>
<surname><![CDATA[Cho]]></surname>
<given-names><![CDATA[SW]]></given-names>
</name>
<name>
<surname><![CDATA[Colovos]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aggressive surgical management of peritoneal carcinomatosis with low mortality in a high-volume tertiary cancer center]]></article-title>
<source><![CDATA[Ann Surg Oncol]]></source>
<year>2008</year>
<volume>15</volume>
<page-range>754-63</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Spiliotis]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Vaxevanidou]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sergouniotis]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of recurrent advanced ovarian cancer: a prospective study]]></article-title>
<source><![CDATA[J BUON]]></source>
<year>2011</year>
<volume>16</volume>
<page-range>74-9</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rossi]]></surname>
<given-names><![CDATA[CR]]></given-names>
</name>
<name>
<surname><![CDATA[Deraco]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[De Simone]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hyperthermic intraperitoneal intraoperative chemotherapy after cytoreductive surgery for the treatment of abdominal sarcomatosis: clinical outcome and prognostic factors in 60 consecutive patients]]></article-title>
<source><![CDATA[Cancer]]></source>
<year>2004</year>
<volume>100</volume>
<page-range>1943-50</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sugarbaker]]></surname>
<given-names><![CDATA[PH]]></given-names>
</name>
<name>
<surname><![CDATA[Alderman]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Edwards]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prospective morbidity and mortality assessment of cytoreductive surgery plus perioperative intraperitoneal chemotherapy to treat peritoneal dissemination of appendiceal mucinous malignancy]]></article-title>
<source><![CDATA[Ann Surg Oncol]]></source>
<year>2006</year>
<volume>13</volume>
<page-range>635-44</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Deraco]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kusomura]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Virzi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy as up front therapy for advanced. EOC: multi-institutional phase II study]]></article-title>
<source><![CDATA[Gynecol Oncol]]></source>
<year>2011</year>
<volume>122</volume>
<page-range>215-20</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Helm]]></surname>
<given-names><![CDATA[CW]]></given-names>
</name>
<name>
<surname><![CDATA[Randall-Whitis]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Martin]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma]]></article-title>
<source><![CDATA[Gynecol Oncol]]></source>
<year>2007</year>
<volume>105</volume>
<page-range>90-6</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yan]]></surname>
<given-names><![CDATA[TD]]></given-names>
</name>
<name>
<surname><![CDATA[Morris]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Shigeki]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Preoperative investigations in the management of peritoneal surface malignancy with cytoreductive surgery and perioperative intraperitoneal chemotherapy: Expert consensus statement]]></article-title>
<source><![CDATA[J Surg Oncol]]></source>
<year>2008</year>
<volume>98</volume>
<page-range>224-7</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Deraco]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bartlett]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Kusamura]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Consensus statement on peritoneal mesothelioma]]></article-title>
<source><![CDATA[J Surg Oncol]]></source>
<year>2008</year>
<volume>98</volume>
<page-range>268-72</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sugarbaker]]></surname>
<given-names><![CDATA[PH]]></given-names>
</name>
<name>
<surname><![CDATA[Welch]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
<name>
<surname><![CDATA[Mohamed]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A review of peritoneal mesothelioma at the Washington Cancer Institute]]></article-title>
<source><![CDATA[Surg Oncol Clin North Am]]></source>
<year>2003</year>
<volume>12</volume>
<page-range>605-21</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pestieau]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Sugarbaker]]></surname>
<given-names><![CDATA[PH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment of primary colon cancer with peritoneal carcinomatosis: comparison of concomitant vs. delayed management]]></article-title>
<source><![CDATA[Dis Colon Rectum]]></source>
<year>2000</year>
<volume>43</volume>
<page-range>1341-8</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dudar]]></surname>
<given-names><![CDATA[TE]]></given-names>
</name>
<name>
<surname><![CDATA[Jain]]></surname>
<given-names><![CDATA[RK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Differential response of normal and tumor microcirculation to hyperthermia]]></article-title>
<source><![CDATA[Cancer Res]]></source>
<year>1984</year>
<volume>44</volume>
<page-range>605-12</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sugarbaker]]></surname>
<given-names><![CDATA[PH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of peritoneal-surface malignancy: the surgeon&#8217;s role]]></article-title>
<source><![CDATA[Langenbecks Arch Surg]]></source>
<year>1999</year>
<volume>384</volume>
<page-range>576-87</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Verwaal]]></surname>
<given-names><![CDATA[VJ]]></given-names>
</name>
<name>
<surname><![CDATA[Van Ruth]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[De Bree]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2003</year>
<volume>21</volume>
<page-range>3737-43</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Elias]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Lefevre]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Chevalier]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2009</year>
<volume>27</volume>
<page-range>681-5</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Franko]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ibrahim]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Gusani]]></surname>
<given-names><![CDATA[NJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis]]></article-title>
<source><![CDATA[Cancer]]></source>
<year>2010</year>
<volume>16</volume>
<page-range>3756-62</page-range></nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jacquet]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Stephens]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Averbach]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Analysis of morbidity and mortality in 60 patients with peritoneal carcinomatosis treated by cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy]]></article-title>
<source><![CDATA[Cancer]]></source>
<year>1996</year>
<volume>77</volume>
<page-range>2622-9</page-range></nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Glehen]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Gilly]]></surname>
<given-names><![CDATA[FN]]></given-names>
</name>
</person-group>
<source><![CDATA[Quantitative prognostic indicators of peritoneal surface malignancy: carcinomatosis, sarcomatosis]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smeenk]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Bex]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Verwaal]]></surname>
<given-names><![CDATA[VJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pseudomyxoma peritonei and the urinary tract: involvement and treatment related complications]]></article-title>
<source><![CDATA[J Surg Oncol]]></source>
<year>2006</year>
<volume>93</volume>
<page-range>20-3</page-range></nlm-citation>
</ref>
<ref id="B29">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Levine]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[Stewart]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Russell]]></surname>
<given-names><![CDATA[GB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: experience with 501 procedures]]></article-title>
<source><![CDATA[J Am Coll Surg]]></source>
<year>2007</year>
<volume>204</volume>
<page-range>943-53</page-range></nlm-citation>
</ref>
<ref id="B30">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stewart]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Shen]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Russell]]></surname>
<given-names><![CDATA[GB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Appendiceal neoplasms with peritoneal dissemination: outcomes after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy]]></article-title>
<source><![CDATA[Ann Surg Oncol]]></source>
<year>2006</year>
<volume>13</volume>
<page-range>624-34</page-range></nlm-citation>
</ref>
<ref id="B31">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[López-Basave]]></surname>
<given-names><![CDATA[HN]]></given-names>
</name>
<name>
<surname><![CDATA[Morales-Vasquez]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Ruiz Molina]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Morbidity and mortality of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: National Cancer institute, Mexico City, Mexico]]></article-title>
<source><![CDATA[ISRN Oncol]]></source>
<year>2011</year>
<page-range>1-6</page-range></nlm-citation>
</ref>
<ref id="B32">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kusamura]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Younan]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Baratti]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique]]></article-title>
<source><![CDATA[Cancer]]></source>
<year>2006</year>
<volume>106</volume>
<page-range>1144-53</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
